Clinical Trial Update: A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating TMC435 in combination with PegIFN alfa-2a and ribavirin for treatment-naïve or treatment-experienced chronic hepatitis C virus infectio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• TMC435

Snippet

Sponsor: Janssen R&D Ireland | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED